FeesSafety
Pluang+

Ether risks breaking key $2,000 support after strong September gains, with $1,850-$1,920 as critical zone.

Technical Signals
26 Oct 2026, 22:54 WIB
Tokenpost
View Source
Neutral
Ether risks breaking key $2,000 support after strong September gains, with $1,850-$1,920 as critical zone.

Ether (ETH) gained 8.77% in September and may either continue its winning streak into October or see a reversal by month-end. Historically, October has been mixed for Ether, closing higher in six out of ten periods since 2016. Analysts warn that a drop below $2,000 could push Ether into a crucial support range between $1,850 and $1,920, described as a "make-or-break zone." A strong bounce from this zone could lead to a relief rally, but failure to reclaim $2,350 soon might see prices testing $2,200 next.

Ether's recent performance is notable as it gained 8.77% in September, with October's outcome still uncertain. For readers following cryptocurrency, here is Pluang's market snapshot as of Oct 27, 2026 02:52 WIB: out of 50 major cryptocurrencies, 16 rose and 32 fell today. Key movers include BAT at Rp2.604 with a 1-day change of -6.01% and a Pluang order activity of 5% Sell / 95% Buy, VET at Rp119 down 4.79% with 91% Sell / 9% Buy, and CAKE at Rp38.790 up 4.72% with 35% Sell / 65% Buy.

More News

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement to announce Q3 2026 financial results on Nov 9 with a webcast.

Exodus Movement, a self-custodial finance and payments platform, will release its third quarter 2026 financial results after market close on November 9, 2026. The company will host a webcast at 5:00 PM ET the same day to discuss the results. Founded ...

Company Fundamentals
Neutral
1 hour ago
Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360 named national pharmacy partner for AstraZeneca's lung cancer drug Zegfrovy.

Onco360, a leading independent specialty pharmacy, has been selected by AstraZeneca as a national pharmacy partner for Zegfrovy (sunvozertinib), a treatment for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. Zegfrovy has s...

Market News
Bullish
1 hour ago
S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions joins SAP PartnerEdge program, boosting its SAP consulting capabilities.

S4A IT Solutions has been accepted into the SAP PartnerEdge program, marking a key milestone in its growth. This partnership enhances S4A's ability to help organizations maximize their SAP investments, especially in areas like asset management and su...

Market News
Bullish
2 hours ago
SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

SEC policy shifts and rising shareholder activism shape 2027 proxy season preparations for public companies

Public companies are facing new challenges for the 2027 proxy season due to changes in SEC policies, evolving shareholder activism strategies, and shifts in institutional investor voting. A virtual roundtable on October 28 will gather experts to disc...

Market News
Neutral
3 hours ago
Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo to release Q3 2026 earnings on Nov 6 with a conference call for analysts.

Gogo Inc., a leading provider of in-flight broadband connectivity, announced it will report its third quarter 2026 financial results on November 6, 2026, before the market opens. The company will hold a conference call with financial analysts the sam...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App